Add to ORKGThe project concerns the use of optimal control methods for computation of EPO (Erythropoietin) doses in hemodialysis patients.publishe
Abstract Background The increasing use of erythropoietins with long half-lives and the tendency to l...
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of an...
This paper describes how Bayesian Networks can be used in combination with compartmental models to p...
Anemia management with erythropoiesis stimulating agents is a di cult task in hemodialysis patients ...
Anemia management with erythropoiesis stimulating agents is a challenging task in hemodialysis patie...
Due to insufficient endogenous production of erythropoietin, chronic kidney disease patients with an...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Early dosing practices and effectiveness of recombinant human erythropoietin. In a national longitud...
The primary objective of this work was to determine the optimal time for administration of an erythr...
Epoetin (recombinant human erythropoietin; EPO) therapy adds a significant cost to the management of...
ABSTRACT: The primary objective of this work was to determine the optimal time for administration of...
Background: For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESA...
Erythropoietin or EPO is a glycoprotein hormone that controls Erythropoiesis, or red blood cell prod...
Abstract Background The increasing use of erythropoietins with long half-lives and the tendency to l...
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of an...
This paper describes how Bayesian Networks can be used in combination with compartmental models to p...
Anemia management with erythropoiesis stimulating agents is a di cult task in hemodialysis patients ...
Anemia management with erythropoiesis stimulating agents is a challenging task in hemodialysis patie...
Due to insufficient endogenous production of erythropoietin, chronic kidney disease patients with an...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Next to physician and employee salaries, the largest single expenditure for most dialysis facilities...
Early dosing practices and effectiveness of recombinant human erythropoietin. In a national longitud...
The primary objective of this work was to determine the optimal time for administration of an erythr...
Epoetin (recombinant human erythropoietin; EPO) therapy adds a significant cost to the management of...
ABSTRACT: The primary objective of this work was to determine the optimal time for administration of...
Background: For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESA...
Erythropoietin or EPO is a glycoprotein hormone that controls Erythropoiesis, or red blood cell prod...
Abstract Background The increasing use of erythropoietins with long half-lives and the tendency to l...
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of an...
This paper describes how Bayesian Networks can be used in combination with compartmental models to p...